UK's Chroma and GlaxoSmithKline Target Macrophages For Anti-Inflammatory UseI
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first Big Pharma deal, Chroma Therapeutics will collaborate with GSK to develop macrophage-targeted small molecules that may provide a safer and lower-cost alternative to certain biologics
You may also be interested in...
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”